A Democratic bill with 2 Republican cosponsors · See all 2 cosponsors
Last activity — Referred to the House Committee on Energy and Commerce.
In committee
Introduced and handed to a committee in the chamber it started in.
The committee holds it, and most bills are never heard from again. A hearing or a committee vote would be news; silence is the usual outcome, and it kills the bill without anyone voting against it.
Its path through Congress
- Introduced
- In Committee
What this bill would do
The MAPS Act aims to improve federal coordination to identify and mitigate health and national security risks. The Secretary of Health and Human Services is tasked with maintaining an "Essential Medicines List" that includes drugs critical for responding to specific threats or those at high risk of shortage. The bill requires a comprehensive risk assessment of the supply chains for these essential medicines. Additionally, the Act mandates a system to map pharmaceutical supply chains using data analytics. This mapping includes everything from raw materials to finished products. Finally, the Secretary must coordinate with other federal agencies and industry stakeholders to monitor these vulnerabilities.
Yes· 3 of 7
- Scored +7
Does this make the country readier for the next outbreak?
The bill strengthens public health preparedness by identifying and mitigating vulnerabilities in the essential medicine supply chain.
- Scored +6
Does this make health care easier to get in general?
The act improves healthcare access by securing the supply chain for essential and life-saving medicines.
- Scored +5
Does this make what the government does easier for the public to see?
The bill increases transparency by requiring reports to Congress on supply chain vulnerabilities.
The opposite
No question was scored the opposite.
Who it would affect, and how
Potential Positive Impacts for People
-
Protection against shortages: The bill requires the creation of an Essential Medicines List that includes drugs at high risk of shortage or those that would cause adverse health outcomes if unavailable (Section 2(a)(2) and Section 2(a)(3)).
-
Enhanced national security: The Act aims to mitigate risks related to chemical, biological, radiological, or nuclear threats (Section 2(a)(1)).
-
Improved supply chain visibility: By mapping supply chains from starting materials to finished forms, the government can better identify vulnerabilities (Section 4(a)(1)).
-
Mitigation of threats: The risk assessment process includes identifying how the Federal Government will mitigate national security risks, potentially using the Defense Production Act of 1950 (Section 3(b)(7)).
Potential Negative Impacts for People
- Cybersecurity risks: While the bill mandates robust cybersecurity measures, the mapping and exchange of detailed pharmaceutical supply chain information creates a need to prevent inappropriate access or unauthorized disclosure (Section 6(c)).
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Tap or hover a score for the reason it gave.
- Healthcare
- Does this make the country readier for the next outbreak? — The bill strengthens public health preparedness by identifying and mitigating vulnerabilities in the essential medicine supply chain. Does this make health care easier to get in general? — The act improves healthcare access by securing the supply chain for essential and life-saving medicines.
- Governance And Ideology
- Does this make what the government does easier for the public to see? — The bill increases transparency by requiring reports to Congress on supply chain vulnerabilities. Does this give the federal government more power? — The bill expands federal oversight and monitoring of the pharmaceutical supply chain.
- Economy And Finance
- Does this give people more protection from unfair business practices? — The bill enhances consumer protection by mitigating the risk of critical drug shortages.
- National Security And Foreign Policy
- Does this better protect the country from computer attacks? — The bill mandates robust cybersecurity measures to protect sensitive pharmaceutical supply chain data.
- Education And Technology
- Does this give people more control over their personal data? — The bill includes requirements for robust cybersecurity to protect sensitive supply chain information.
- 6/23/2026
- 1 Cosponsor added.
- 6/26/2025
- Referred to the House Committee on Energy and Commerce.
- 1 Cosponsor added.
- Introduced in House
One bill Congress.gov lists as related to this one — companions in the other chamber, earlier versions, and bills this one absorbed or was folded into.
Don BaconRepublican · Nebraska
Dan CrenshawRepublican · Texas